Mouse Anti-LATS2 Recombinant Antibody (2D3) (CBMAB-L0733-YJ)

Han, H., Nakaoka, H. J., Hofmann, L., Zhou, J. J., Yu, C., Zeng, L., ... & Wang, W. (2022). The hippo pathway kinases LATS1 and LATS2 attenuate cellular responses to heavy metals through phosphorylating MTF1. Nature cell biology, 24(1), 74-87.

Jin, D., Guo, J., Wu, Y., Yang, L., Wang, X., Du, J., ... & Sun, H. (2020). m 6 A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC. Molecular cancer, 19, 1-24.

Kim, E., Kang, J. G., Kang, M. J., Park, J. H., Kim, Y. J., Kweon, T. H., ... & Cho, J. W. (2020). O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proceedings of the National Academy of Sciences, 117(25), 14259-14269.

Xie, S. C., Zhang, J. Q., Jiang, X. L., Hua, Y. Y., Xie, S. W., Qin, Y. A., & Yang, Y. J. (2020). LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell death & disease, 11(8), 676.

Tang, F., Gao, R., Jeevan-Raj, B., Wyss, C. B., Kalathur, R. K., Piscuoglio, S., ... & Christofori, G. (2019). LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. Nature communications, 10(1), 5755.

Shi, Y., Geng, D., Zhang, Y., Zhao, M., Wang, Y., Jiang, Y., ... & Zhou, X. (2019). LATS2 inhibits malignant behaviors of glioma cells via inactivating YAP. Journal of Molecular Neuroscience, 68, 38-48.

Tsoi, M., Morin, M., Rico, C., Johnson, R. L., Paquet, M., Gévry, N., & Boerboom, D. (2019). Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance. The FASEB Journal, 33(10), 10819.

Guo, C., Liang, C., Yang, J., Hu, H., Fan, B., & Liu, X. (2019). LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma. Oncology reports, 41(5), 2753-2761.

Shi, X., Liu, Z., Liu, Z., Feng, X., Hua, F., Hu, X., ... & Nie, F. (2018). Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer. EBioMedicine, 37, 177-187.

Furth, N., Pateras, I. S., Rotkopf, R., Vlachou, V., Rivkin, I., Schmitt, I., ... & Aylon, Y. (2018). LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state. Life science alliance, 1(5).

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols